Use access key #2 to skip to page content.
$4.79 0.04 (0.84%)
10/7/2008 10:41 AM

Exelixis, Inc. (EXEL)

CAPS Rating:
*****

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

View All Commentary (EXEL)

Recs

2

Avatar sowfar (34.03) Submitted: 6/08/06 2:50 PM : Outperform Start Price: $10.37 EXEL Score: -38.73

EXEL has a big pipeline of cancer drugs. Steady flow of news likely. Biotech is out of favour as of writing. Company's management seems good and has long-term outlook. Connections with big pharma.

Report this Post Replies: 0 | Reply

Featured Broker Partners